Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 310, Issue 1, 2016, Pages G26-G33

  Hou, Yanan ^a   Ernst, Stephen A ^a   Heidenreich, Kaeli ^a   Williams, John A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Amylase secretion; cAMP; Glucagon like peptide 1 receptor; Pancreatic acini

Indexed keywords

AMYLASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MESSENGER RNA; GLP1R PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

ACINAR CELL; AMYLASE RELEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL STRUCTURE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME RELEASE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; AGONISTS; ANIMAL; C57BL MOUSE; CELL SHAPE; CYTOLOGY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PANCREAS ISLET; PHOSPHORYLATION; SECOND MESSENGER; SECRETION (PROCESS);

ACINAR CELLS; AMYLASES; ANIMALS; CELL SHAPE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INCRETINS; ISLETS OF LANGERHANS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; RNA, MESSENGER; SECOND MESSENGER SYSTEMS;

EID: 84953261551     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00293.2015     Document Type: Article

References (56)

1. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 358: 1970-1972, 2008.
2. Baldescu R, Chirulescu Z. Study of interrelationship between Zn, Ca and Mg seric concentrations in healthy subjects comparatively with diverse forms of cancer. Rom J Intern Med 32: 203-208, 1994.
3. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and -independent pathways. Circulation 117: 2340-2350, 2008.
4. Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52: 124-132, 2003.
5. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Cξ activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 50: 2237-2243, 2001.
6. Chaudhuri A, Kolodecik TR, Gorelick FS. Effects of increased intracellular cAMP on carbachol-stimulated zymogen activation, secretion, and injury in the pancreatic acinar cell. Am J Physiol Gastrointest Liver Physiol 288: G235-G243, 2005.
7. Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, Boyd AE 3rd. Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133: 1907-1910, 1993.
8. Dore DD, Seeger JD, Chan AK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25: 1019-1027, 2009.
9. Drucker DJ. Glucagon-like peptides. Diabetes 47: 159-169, 1998.
10. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagonlike peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84: 3434-3438, 1987.
11. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33: 428-433, 2010.
12. Fehmann HC, Jiang J, Schweinfurth J, Dorsch K, Wheeler MB, Boyd AE 3rd, Goke B. Ligand-specificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells. Z Gastroenterol 32: 203-207, 1994.
13. 2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 48: 1979-1986, 1999.
14. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520, 1998.
15. Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53: 730-740, 2010.
16. Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagonlike peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211: 169-174, 1987.
17. Hou Y, Ernst SA, Stuenkel EL, Lentz SI, Williams JA. Rab27A is present in mouse pancreatic acinar cells and is required for digestive enzyme secretion. PLos One 10: e0125596, 2015.
18. Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53: 552-561, 2010.
19. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19: 567-575, 2013.
20. Koehler JA, Baggio LL, Cao X, Abdulla T, Campbell JE, Secher T, Jelsing J, Larsen B, Drucker DJ. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 64: 1046-1056, 2015.
21. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58: 2148-2161, 2009.
22. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304, 1987.
23. Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest 122: 388-402, 2012.
24. Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 40: 1074-1082, 1995.
25. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616-619, 1987.
26. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol Endocrinol Metab 271: E808-E813, 1996.
27. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
28. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32: 834-838, 2009.
29. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983, 2009.
30. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
31. Pearson RB, Kemp BE. Protein kinase phosphorylation site sequences and consensus specificity motifs: tabulations. Methods Enzymol 200: 62-81, 1991.
32. Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, Mseeh F, Shadoan MK, Sands A, Zambrowicz B, Ding ZM. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/ glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345: 250-259, 2013.
33. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor- or not? Endocrinology 154: 4-8, 2013.
34. Rajan S, Dickson LM, Mathew E, Orr CM, Ellenbroek JH, Philipson LH, Wicksteed B. Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic beta-cells via protein kinase A. Mol Metab 4: 265-276, 2015.
35. Raufman JP, Singh L, Singh G, Eng J. Truncated glucagon-like peptide- 1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 267: 21432-21437, 1992.
36. Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, Gribble FM, Reimann F. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63: 1224-1233, 2014.
37. Sabbatini ME, D'Alecy L, Lentz SI, Tang T, Williams JA. Adenylyl cyclase 6 mediates the action of cyclic AMP-dependent secretagogues in mouse pancreatic exocrine cells via protein kinase A pathway activation. J Physiol 591: 3693-3707, 2013.
38. Sans MD, Sabbatini ME, Ernst SA, D'Alecy LG, Nishijima I, Williams JA. Secretin is not necessary for exocrine pancreatic development and growth in mice. Am J Physiol Gastrointest Liver Physiol 301: G791-G798, 2011.
39. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258, 1996.
40. 125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig. Regul Pept 53: 47-59, 1994.
41. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49: 741-748, 2000.
42. Swanson KT. Dogs, dextran, and dilatation: a story of empiricism run wild. Catheterization Cardiovasc Diagn 32: 203-205, 1994.
43. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47: 530-537, 1998.
44. Tatarkiewicz K, Belanger P, Gu G, Parkes D, Roy D. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab 15: 417-426, 2013.
45. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56: 841-851, 2008.
46. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609 -613, 2001.
47. Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Soeborg H, Knudsen LB. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 303: E253-E264, 2012.
48. Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagonlike- peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol 28: 391-402, 2015.
49. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78 -107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673, 1993.
50. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol Gastrointest Liver Physiol 275: G984-G992, 1998.
51. Williams JA. GLP-1. In: Pancreapedia: Exocrine Pancreas Knowledge Base. Ann Arbor, MI: University of Michigan, 2014. DOI:10.3998/ panc.2014.7.
52. Williams JA. Isolation of rodent pancreatic acinar cells and acini by collagenase digestion. In: Pancreapedia: Exocrine Pancreas Knowledge Base. Ann Arbor, MI: University of Michigan, 2010. DOI:10.3998/ panc.2010.18.
53. Williams JA, Goldfine ID. The insulin-pancreatic acinar axis. Diabetes 34: 980-986, 1985.
54. Williams JA, Korc M, Dormer RL. Action of secretagogues on a new preparation of functionally intact, isolated pancreatic acini. Am J Physiol 235: 517-524, 1978.
55. Williams JA, Yule DI. Stimulus-secretion coupling in pancreatic acinar cells. In: Physiology of the Gastrointestinal Tract (5th ed.), edited by Johnson L. New York: Academic, 2012, p. 1361.
56. Yusta B, Estall J, Drucker DJ. Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem 277: 24896 -24906, 2002.